The Urolithiasis Management Devices Market, estimated at USD 1,861.7 Mn in 2025, is expected to exhibit a CAGR of 4.8% and reach USD 2,584.9 Mn by 2032.
The industry is witnessing significant growth driven by rising demand for advanced, reliable, and cost-effective medical devices across diagnostic, therapeutic, and monitoring applications. Rapid advancements in device design, digital health integration, and adoption of minimally invasive technologies are reshaping the competitive landscape. Furthermore, supportive regulatory frameworks, increasing healthcare investments, and the growing focus on patient-centric care are expected to create new growth avenues for market players.
Increase in organic strategies such as regulatory authority clearance for the urolithiasis management device to the market players is expected to drive the global urolithiasis management devices market by the forecast period. For instance, on February 3, 2025, Boston Scientific Corporation, a biomedical devices manufacturer announced that the company received U.S. Food and Drug Administration FDA’s clearance for LithoVue Elite single-use digital flexible ureteroscope, a device used to visualize and treat the stone, for the treatment of urinary disorders.
Global Urolithiasis Management Devices Market– Impact of Coronavirus (COVID-19) Pandemic
The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdowns in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.
Furthermore, healthcare providers were facing challenges in terms of additional manpower, equipment, consumables, and other resources which were required to ensure safety in hospitals and provide treatment to patients and devices to the ambulatory surgical centers. This has impacted the overall healthcare market negatively.
During the COVID-19 pandemic, the urolithiasis management device market was significantly impacted due to an increase in the demand for treatment options for kidney stone-related disease and a decrease in the supply of devices to treat urolithiasis due to restrictions imposed by the government during COVID-19. For instance, in October 2025, data was published by Elsevier, a academic publishing company, according to which, urolithiasis emergency admissions have decreased significantly in Rome during the COVID-19 epidemic. Individuals who were admitted to the emergency department had greater difficulties, required hospitalization more frequently, and early stone removal was preferable over simple urine drainage in terms of clinical care.